These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25558595)

  • 1. [Apolipoprotein A-I and B in laboratory diagnostics of dyslipidemia--what benefits do we gain compared with cholesterol measurements?].
    Leiviskä J; Sundvall J; Jauhiainen M; Laatikainen T
    Duodecim; 2014; 130(22-23):2331-7. PubMed ID: 25558595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.
    Wallenfeldt K; Bokemark L; Wikstrand J; Hulthe J; Fagerberg B
    Stroke; 2004 Oct; 35(10):2248-52. PubMed ID: 15345795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study.
    Bruno G; Merletti F; Biggeri A; Bargero G; Prina-Cerai S; Pagano G; Cavallo-Perin P
    Diabetologia; 2006 May; 49(5):937-44. PubMed ID: 16525840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intake.
    Tognon G; Berg C; Mehlig K; Thelle D; Strandhagen E; Gustavsson J; Rosengren A; Lissner L
    PLoS One; 2012; 7(7):e40878. PubMed ID: 22848405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
    Olson EJ; Pearce GL; Jones NP; Sprecher DL
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
    J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
    Walldius G; Jungner I
    J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults.
    Zheng S; Han T; Xu H; Zhou H; Ren X; Wu P; Zheng J; Wang L; Zhang M; Jiang Y; Chen Y; Qiu H; Liu W; Hu Y
    BMJ Open; 2017 Jan; 7(1):e014038. PubMed ID: 28110289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.
    Kaneva AM; Potolitsyna NN; Bojko ER; Odland JØ
    Dis Markers; 2015; 2015():591454. PubMed ID: 25852220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
    Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
    Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
    Andrikoula M; McDowell IF
    Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study.
    Ndumele CE; Matsushita K; Astor B; Virani SS; Mora S; Williams EK; Hoogeveen RC; Blumenthal RS; Sharrett AR; Ballantyne CM; Coresh J
    Eur J Prev Cardiol; 2014 Jul; 21(7):866-75. PubMed ID: 23109406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
    Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
    Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.